Health technology company Hyperfine Research Inc said on Monday that it plans to use the world's first portable, low-cost magnetic resonance imaging (MRI) system at the bedside of patients in the neuro intensive care unit of Yale New Haven Hospital (YNHH) under an agreement with Yale School of Medicine.
Through the Point-of-Care (POC) MRI, Hyperfine aims to make MRI accessible and available anywhere, anytime, to any patient who needs it. The new MRI system can move directly to the bedside, plug into a wall outlet and operate in any healthcare setting.
In partnership with the American Heart Association, Yale New Haven Hospital (YNHH) is the first hospital to use the Hyperfine POC MRI system on patients. YNHH is helping test the clinical workflow, user interface and image quality of Hyperfine's system.
Under the two year study, the company aims to overcome barriers that have prevented the routine use of MRI on unstable neurology intensive care unit patients who cannot be transported.
To date, YNHH has completed 138 brain MRI exams of 123 patients with known, acute neuropathology, as well as ischemic stroke, hematomas, tumors and hydrocephalus. The preliminary findings of the research are expected to be announced in early 2020.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA